We have previously developed efficient peptide-based nucleic acid delivery vectors PF14 and NF55, where we have shown that these vectors preferentially transfect lung tissue upon systemic administration with the nucleic acid. In the current work, we have explored the utilization and potential of these vectors for the lung-targeted gene therapy. Accordingly, we assessed the efficacy of these peptides in (i) two different lung disease models -acute lung inflammation and asthma in mice and (ii) using two different nucleic acid cargos -siRNA and pDNA encoding shRNA. Using RNAi against cytokine TNFα, we showed efficient anti-inflammatory effects in both disease models and observed decreased disease symptoms. Our results highlight the potential of our transfection vectors for lung gene therapy.
hypothesized that the peptide carriers exert huge potential for lung-targeted delivery and it is reasonable to assess their efficacy in pulmonary conditions. The lung delivery is safe. It is paramount that the delivery system be safe. A well-known fact from previous studies is that cationic transfection reagents can exert adverse respiratory effects [10] [11] [12] . In our previous studies, we have specifically addressed this problem and we recently proposed an alternative "safe" formulation for our peptides and nucleic acid cargo that offers nontoxic transfection 10 . Indeed, we asked a pathologist to assess histological slices from the animals that received the peptides and confirmed that there are no harmful effects ( Supplementary Fig. S3 ) and it is safe to proceed with in vivo models.
RNAi with the peptide vectors reduces LPS-induced lung inflammation. Although reporter assays
are excellent for the quantification, they contain artificial (albeit well-optimized) biological systems that may not occur in real life. To assess if our gene therapeutic intervention would be achievable in the real biological system, we started with a simple model of lipopolysaccharide (LPS) -induced inflammation. LPS induces acute inflammation that resembles acute and strong bacterial infection. LPS is recognized by macrophages that get activated and start producing and secreting proinflammatory cytokine TNFα, which in turn act as chemotaxis to numerous downstream cytokines and activation signal to other cells ( Fig. 2a) 13 . Therefore, inhibition of TNFα represents an early step in the inflammatory cascade and is therapeutically important target.
Because we aimed at inhibiting TNFα with RNAi, we first validated the siTNF in primary macrophages ( Fig. 2a ). For that, we cultured primary macrophages from the mouse bronchoalveolar lavage, activated these with LPS, and transfected siTNF using RNAiMax or our peptides ( Fig. 2b ). We could easily knock down TNFα, more efficiently than with RNAiMax ( Fig. 2c ). This encouraged us to proceed in vivo and, using LPS to induce acute inflammation, assess the same inhibition. We induced lung inflammation in mice ( Fig. 2b) and again attempted to inhibit TNFα. This time we used both siRNA and a plasmid encoding short hairpin RNA (pshTNF, see Supplementary Fig. S4 and the "Methods" section about construction of the plasmid), administered using our peptides i.v. Using a plasmid offers the theoretical advantage of longer exposure to the therapeutic, because the plasmid constitutively expresses shRNA and the therapeutic is thus naturally "renewed".
Name Sequence

PF14
Stearyl-AGYLLGKLLOOLAAAALOOLL-NH 2
NF55
(Stearyl-AGYLLG)δ-OINLKALAALAKAIL-NH 2 Now the important question was -could the treatment affect inflammation? Since the progression of acute inflammation is extremely fast, and it is not possible to capture first the upregulation and then subsequent knockdown of the TNFα (we could not detect changes in TNFα expression within our 28 h timeframe between LPS administration, siRNA treatment, and tissue collection), we proceeded directly to evaluation of the clinical phenotype. This was assessed from lung histology ( Supplementary Fig. S5 ) and the estimation of the presence of various inflammation markers, such as perivascular, peribronchial, alveolar infiltration of lymphocytes, and edema ( Supplementary Fig. S6 ). Perivascular infiltration scores (PVI, presence of lymphocytes around the vasculature) are shown in Fig. 2d . We were encouraged to see that both of our peptides -NF55 and PF14 -were efficient in reducing lung inflammation and both nucleic acid types -siRNA and plasmid -were efficient (Fig. 2d ).
RNAi with the peptide vectors reduces inflammation in a model of asthma.
As a final step, we chose a mouse model that allowed treatment and assessment over a longer time period and in chronic pathology -a situation where application of gene therapy is extremely potential. We used a well characterized model of murine asthma, induced by general sensitization with a foreign protein and an adjuvant and then local administration of the sensitizer into the lungs 14 . This was followed by treatment with the siRNA or pDNA (Fig. 3a ). With this model, there is a clear and distinct period where inflammatory processes develop ( Fig. 3a www.nature.com/scientificreports www.nature.com/scientificreports/ treatment effects take place (days 29-32). Indeed, following the murine asthma model and performing RNAi treatment, qPCR analysis revealed potent knockdown of the TNFα gene, mediated by both siTNF and pshTNF, and with both of our peptides NF55 and PF14 (Fig. 3b ). As can be seen from the figure, the untreated animals (or rather, animals receiving naked, nonvectorized nucleic acid) display TNFα gene expression levels ranging from low to very high (up to 300% from the average), whereas the treated animals show mostly low TNFα expression levels with narrow variability. This demonstrates significant gene knockdown in the lung and is in good agreement with our hypothesis about lung targeting with our peptides. Finally, similarly to the LPS model, we assessed the presence of inflammation from the lung histology, following the treatment with nucleic acid therapeutics. As can be seen from the Fig. 3c, Supplementary Figs. S7 and S8 , the treatment was effective in most cases: siTNF, vectorized with either of the peptides, as well as PF14 with the pshTNF significantly reduced the PVI score. When comparing the gene knockdown ( Fig. 3b ) and respective inflammatory phenotype (Fig. 3c ), one can observe ubiquitous efficiency of both peptides, with both therapeutic cargoes (siRNA and pDNA) in knocking down the target gene. The reason why quite not the same efficacy is not translated to anti-inflammatory phenotype (reduced inflammation in 3 groups out of 4) may be that that in case of asthma, knockdown of just one gene may not be enough to reverse the whole syndrome, but rather partly inhibits the inflammatory processes. Moreover, it can not be ruled out that other gene targets might have had even stronger therapeutic effect than TNFα.
Conclusions
In the current report we aimed to demonstrate effective nucleic acid delivery into the lung. We have recently developed two peptides that are well usable in vivo 2,3 , because they show excellent efficacy and safety profile. However, their relevance beyond sensitive reporter models and utility in medicine has been demonstrated only in limited cases. As an example of this, we have previously demonstrated cancer delivery by adding targeting components to the delivery vector 3, 15 . In the current work however, we utilized the native biodistribution bias of the carrier itself. Indeed, by taking advantage of the underlying property of our CPPs PF14 and NF55 to preferentially and efficiently transfect the lung 2,3 , we just adjusted the vector into preclinical models associated with pulmonary www.nature.com/scientificreports www.nature.com/scientificreports/ function. Our main aim was to demonstrate the delivery prowess of the peptide vectors and achieve measurable gene modulation in physiological conditions. Indeed, as we hypothesized, the peptide vectors PF14 and NF55 demonstrated efficient gene knockdown through RNAi in lungs, both by using siRNA and plasmid DNA as the cargo therapeutic. Moreover, we also demonstrated measurable physiological changes and achieved beneficial therapeutic effects in preclinical murine models. The current work represents a large step towards clinical application of nucleic acid therapies, using peptide-based drug delivery vectors.
Methods
All methods were carried out in accordance with relevant guidelines and regulations.
The following software was used to generate the graphical content: Figure 1A -Zen software (Zeiss); Figs. 1B, 2C,D, 3B,C, S2, S6, S8 -GraphPad Prism; Fig. 2a ,b -Symyx Draw, Adobe Illustrator; Figs. 2a,b , 3a -Adobe Illustrator; Fig. S4 -Benchling data export. (Table 1) were synthesized in a stepwise manner in a 0.1 mmol scale on an automated peptide synthesizer (Biotage Initiator + Alstra) by using fluorenylmethyloxycarbonyl (Fmoc) solid phase peptide synthesis strategy with Rink-amide ChemMatrix resin (0.45 mmol/g loading) to obtain C-terminally amidated peptides as described previously 3 . Briefly, N-terminally stearylated peptides were prepared by treatment of peptidyl resin with 5 equiv of stearic acid (Sigma-Aldrich), 4 equiv of HOBt/HBTU (MultiSynTech), and 8 equiv of DIEA (Sigma-Aldrich) in DMF/DCM for 18 h. The final cleavage was performed by treating with 95% TFA/2.5% TIS/2.5% water for 2 h at room temperature. Peptides were purified by RP-HPLC using a C4 column (Phenomenex Jupiter C4, 5 μm, 300 Å, 250 × 10 mm) and 5-80% acetonitrile (0.1% TFA) gradient. The molecular weight was verified by MALDI-TOF mass-spectrometry (Brucker Microflex LT/SH, USA), and purities were >90% as determined by analytical HPLC.
Synthesis of peptides. The peptides
Complex formation. Complexes of nucleic acid and the CPP carriers were formed in MQ water, at N/P = 2 (nitrogen/phosphate ratio 2), as detailed in 10 . Briefly, the complexes were formed in 100 µL of MQ, allowed to incubate for 40 minutes, after which 100 µL of 10% glucose was added and immediately injected (final injection in 200 µL in 5% glucose). The standard injected nucleic acid dose was 1.0 mg/kg.
The siRNA sequences are from the ref. 16 as follows: siTNFsense 5′-pGUCUCAGCCUCUUCUCAUUCCUGct-3′, siTNFantisense 5′-AGCAGGAAUGAGAAGAGGCUGAGACAU-3′, where the RNA bases are uppercase, DNA bases are lowercase, and "p" is a 5′-phosphate. The oligonucleotides were ordered from Metabion, Germany.
Development of plasmid encoding the short hairpin (pshTNF).
The plasmid encoding short hairpin respective to the siTNF was constructed into the backbone of the pCpGfree-siRNA (Invivogen pCpGfree-siRNA, cat no kcpgf-sirna). The choice of the backbone was based on the following characteristics: (i) The backbone has been specifically designed for obtaining plasmid devoid of CpG dinucleotides for increased compatibility with the eukaryotes. (ii) Instead of the usual use of CMV or SC40 promoters, the plasmid incorporates mammalian 7SK promoter, again allowing increased mammalian compatibility.
The insert is as follows:
5′-ACCTC-GTCTCAGCCTCTTCTCATTCCTG-TCAAGAG-CAGGAATGAGAAGAGGCTGAGAC-TT-3′
The siRNA stems are marked with bold. The plasmid map can be found in Supplementary Fig. S4 .
Animal procedures. All the animal experiments and procedures described in this report have been approved by the Estonian laboratory animal ethics committee (the "Project Authorization Committee", enforced from the Article 36 of the EU Directive 2010/63) with the approval no 110, dated Jun 12, 2017. This committee is certified to evaluate and authorize animal experimentation projects in the EU state and follows the national (Estonian) guidelines (the Animal Protection Act, issued by the Estonian Parliament and enforced with the § 82 of the Act) and EU guidelines (2010/63/EU). Balb/c mice were used, males and females at equal numbers, with the age of 8-10 week old at the time of injecting the test substances (peptide carriers).
Anesthesia.
Standard anesthesia dose is defined as a mixture of 75 mg/kg ketamine (Bioketan, Vetoquinol, France) and 1 mg/kg dexmedetomidine (Dorbene, Laboratorios SYVA, Spain) i.p in saline. Some procedures were performed with reduced amount of anesthetic and in these cases the reduced amount has been indicated in the relevant section. Where relevant, the anesthesia was blocked using the α2-adrenergic antagonist atipamezole hydrochloride (Antisedan, Pfizer), 1 mg/kg s.c (these cases are again indicated in the relevant sections).
BAL procedure and cultivation of the macrophages. Mice were euthanized immediately prior to lavage by anesthetic overdose. Trachea was exposed and cannulated. 0.5 mL of ice-cold PBS-EDTA (sterile Mg-and Ca-free PBS + 0.6 mM EDTA) was injected into the lungs and using a 3-way valve, aspirated into another syringe. The cycle was repeated with new PBS for 8 times (8 washes with 1 mL of PBS-EDTA). Viable and non-viable cells were counted from the lavage using trypan blue. The lavage was then centrifuged at 450 g × 10 min and the cell pellet was re-suspended in warm RPMI and maintained at standard mammalian cell culture conditions (37 °C, 5% CO 2 ).
LPS-induced acute lung inflammation.
In order to induce the inflammation, LPS (2.5 mg/kg in saline) was administered intranasally twice, at 0 h and +24 h. For this, the animals were anesthetized with ½ of the
